New drug combo aims to outsmart resistant breast cancer
NCT ID NCT03939897
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding a drug called copanlisib to the standard two-drug therapy (fulvestrant and abemaciclib) can better control hormone receptor-positive, HER2-negative metastatic breast cancer that has stopped responding to hormone therapy. The study involves 24 participants and primarily looks at safety and side effects, while also measuring how long the cancer stays under control. The goal is to find a more effective treatment option for this type of advanced breast cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Copanlisib (added to fulvestrant and abemaciclib)
What this could lead to
If it works, this could lead to a more effective treatment option for people with hormone receptor-positive, HER2-negative metastatic breast cancer that has stopped responding to hormone therapy.
What could go wrong
This is a very early phase I trial with only 24 participants, so the main goal is safety, not effectiveness. The added drug may cause more side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bellevue Hospital Center
New York, New York, 10016, United States
-
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Siteman Cancer Center at Christian Hospital
St Louis, Missouri, 63136, United States
-
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376, United States
-
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141, United States
-
Siteman Cancer Center-South County
St Louis, Missouri, 63129, United States
-
UC Irvine Health Cancer Center-Newport
Costa Mesa, California, 92627, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, 40536, United States
-
Wake Forest University Health Sciences
Winston-Salem, North Carolina, 27157, United States
-
Wake Forest University at Clemmons
Clemmons, North Carolina, 27012, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States